Plus Therapeutics, Inc. announced on August 15, 2025, that it reported stockholders’ equity of $3 million as of June 30, 2025. This figure satisfies Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity.
The company had previously received a delist determination from Nasdaq on June 3, 2025, for non-compliance with the Equity Rule. Following a timely request, the Nasdaq Hearings Panel granted an extension for the company to evidence compliance.
The filing of the Form 10-Q for the quarter ended June 30, 2025, on August 14, 2025, confirmed the company's return to compliance. The company now awaits Nasdaq’s official confirmation of this evidenced compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.